<div id="readability-page-1"><p>Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals and keeping the price target at $43.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Debanjana Chatterjee’s rating is based on the promising outlook for EyePoint Pharmaceuticals, particularly with its wet AMD therapy, Duravyu, which is expected to have pivotal trial readouts by 2026. The company has pursued a well-established regulatory path for wet AMD approval, which is seen as a strategic advantage compared to other companies taking more innovative approaches. <br/> EyePoint’s financial position is also strong, with significant cash reserves that provide a solid foundation for its ongoing and future research and development activities. The market dynamics and potential paradigm shifts in wet AMD treatments further support the Buy rating, as EyePoint’s therapies could play a significant role in addressing unmet needs in this space.</p> <p>In another report released on December 9, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.</p></div>

EYPT

<p>Analyst Debanjana Chatterjee from JonesTrading maintains a Buy rating on EyePoint Pharmaceuticals, with a $43.00 price target, citing promising wet AMD therapy, Duravyu, and strong financial position. EyePoint's strategic regulatory path and market dynamics support the rating. Mizuho Securities also reiterates a Buy rating with a $33.00 target.</p>

Buy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD Therapy